BetterLife is a pre-revenue biopharmaceutical company developing patented drug candidates for neuropsychiatric and antiviral disorders. BetterLife operates entirely in the research and development stage and has no products currently on the market. The company’s pipeline includes BETR-001, a non-hallucinogenic LSD derivative for treating major depressive disorder, anxiety, and neuropathic pain. BetterLife uses a proprietary manufacturing process to produce BETR-001 without using LSD as a starting material, which avoids Schedule 1 controlled substance restrictions. This candidate is designed for patient self-administration and is currently in the preclinical stage. BetterLife also develops MM-001, a topical cream for HPV-induced cervical intraepithelial neoplasia intended as a non-invasive alternative to surgery. MM-001 is a clinical-stage candidate, though BetterLife is reassessing timing for future trials while developing its own proprietary formulation. MM-003 is an inhaled formulation targeting respiratory viral infections. BetterLife does not own manufacturing facilities and instead uses contract development and manufacturing organizations. The company’s business model involves funding operations through equity financing to advance candidates through clinical milestones and regulatory approval.